Chemoinformaics analysis of E-2-Tetradecen-1-ol
| Molecular Weight | 212.377 | nRot | 11 |
| Heavy Atom Molecular Weight | 184.153 | nRig | 0 |
| Exact Molecular Weight | 212.214 | nRing | 0 |
| Solubility: LogS | -0.387 | nHRing | 0 |
| Solubility: LogP | 1.041 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 43 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 15 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 28 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 14 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 42.8522 |
| nHD | 1 | BPOL | 28.0898 |
| QED | 0.537 |
| Synth | 2.361 |
| Natural Product Likeliness | 0.632 |
| NR-PPAR-gamma | 0.003 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0 |
| Pgp-sub | 0.909 |
| HIA | 0.007 |
| CACO-2 | -4.192 |
| MDCK | 0.0000823 |
| BBB | 0.883 |
| PPB | 0.212069 |
| VDSS | 1.102 |
| FU | 0.664324 |
| CYP1A2-inh | 0.272 |
| CYP1A2-sub | 0.741 |
| CYP2c19-inh | 0.036 |
| CYP2c19-sub | 0.776 |
| CYP2c9-inh | 0.016 |
| CYP2c9-sub | 0.385 |
| CYP2d6-inh | 0.011 |
| CYP2d6-sub | 0.398 |
| CYP3a4-inh | 0.008 |
| CYP3a4-sub | 0.235 |
| CL | 11.28 |
| T12 | 0.771 |
| hERG | 0.022 |
| Ames | 0.008 |
| ROA | 0.027 |
| SkinSen | 0.162 |
| Carcinogencity | 0.27 |
| EI | 0.994 |
| Respiratory | 0.093 |
| NR-Aromatase | 0.003 |
| Antiviral | Yes |
| Prediction | 0.797128 |